Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2018 Jul 4;16(3):3439–3446. doi: 10.3892/ol.2018.9078

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright: © Hu et al.

This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.

PMC Copyright notice

Figure 2. — In vitro and in vivo characterization of LIXC-004NA and LIXC-004SR cell lines. (A) IHC staining of the cultured cells under phase contrast microscopy (upper panels), cytokeratin (middle panels) and vimentin (lower panels; magnification, ×200). (B) Short-tandem repeat analyses of the two cell lines and the original PDX tumor. (C) Tumor growth curves (left panels) and images (right panels) of the tumors in response to treatment with vehicle or sorafenib. (D) Hematoxylin and eosin staining of original 004 PDX tumor (left panels), 004NA tumor (middle panels) and 004SR tumor (right panels; magnification, ×100). (E) IHC using anti-CD34 antibody (left panels; magnification, ×100), and blood vessel density by quantification of the percentage of CD34⁺ pixels (right panel). ***P<0.001 by two-way analysis of variance. IHC, immunohistochemistry; 004 PDX, LIX-004 PDX; 004NA, LIXC-004NA; 004SR, LIXC-004SR; Sora, sorafenib; CD, cluster of differentiation.